Vanguard Group Inc Landos Biopharma, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.26 - $0.55 $20,564 - $43,501	-79,094 Reduced 76.72%	23,995 $7,000
Q4 2022 Feb 10, 2023	SELL	$0.22 - $0.51 $13,974 - $32,394	-63,519 Reduced 38.12%	103,089 $51,000
Q3 2022 Nov 14, 2022	BUY	$0.67 - $1.26 $26,165 - $49,206	39,053 Added 30.62%	166,608 $108,000
Q2 2022 Aug 12, 2022	SELL	$0.6 - $1.5 $18,867 - $47,169	-31,446 Reduced 19.78%	127,555 $93,000
Q1 2022 May 13, 2022	SELL	$1.44 - $5.22 $209,947 - $761,060	-145,797 Reduced 47.83%	159,001 $234,000
Q4 2021 Feb 14, 2022	BUY	$4.7 - $15.0 $18 - $60	4 Added 0.0%	304,798 $1.46 Million
Q3 2021 Nov 12, 2021	SELL	$9.77 - $15.77 $3,820 - $6,166	-391 Reduced 0.13%	304,794 $4.45 Million
Q2 2021 Aug 13, 2021	BUY	$9.26 - $12.53 $2.83 Million - $3.82 Million	305,185 New	305,185 $3.52 Million

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.